Academic literature review

• Trichkova, Kremena Petrova; Görtler, Franziska Stilla Maria; Bjørge, Line et al. (2024). Assessment of Variables Related to the Risk of Severe Adverse Events in Cutaneous Melanoma Patients Treated with Immune Checkpoint Inhibitors. (external link)

Academic article

• Schuster, Cornelia; Akslen, Lars Andreas; Straume, Oddbjørn (2023). β2-adrenergic receptor expression in patients receiving bevacizumab therapy for metastatic melanoma. (external link)
• Aamdal, Elin; Jacobsen, Kari Dolven; Straume, Oddbjørn et al. (2021). Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up. (external link)
• Hugdahl, Emilia Signe; Bachmann, Ingeborg M.; Schuster, Cornelia et al. (2019). Prognostic value of uPAR expression and angiogenesis in primary and metastatic melanoma. (external link)
• Schuster, Cornelia; Akslen, Lars A.; Stokowy, Tomasz et al. (2019). Predictive value of angiogenic proteins in patients with metastatic melanoma treated with bevacizumab monotherapy. (external link)
• Forthun, Rakel Brendsdal; Hovland, Randi; Schuster, Cornelia et al. (2019). ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab. (external link)
• Schuster, Cornelia; Akslen, Lars A.; Straume, Oddbjørn (2016). Expression of Heat Shock Protein 27 in melanoma metastases is associated with overall response to bevacizumab monotherapy: Analyses of predictive markers in a clinical phase II study. (external link)
• Schuster, Cornelia; Eikesdal, Hans Petter; Puntervoll, Hanne Eknes et al. (2012). Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension. (external link)

Academic chapter/article/Conference paper

• Dillekås, Hanna; Schuster, Cornelia; Davidsen, Kjersti et al. (2022). The Role of the Microenvironment in Tumor Promoting Stress Responses. (external link)
• Straume, Oddbjørn; Schuster, Cornelia (2017). The Tumor Microenvironment in Cutaneous Melanoma: Friend or Foe. (external link)

Abstract

• Schuster, Cornelia; Gausdal, Gro; Gjertsen, Bjørn Tore et al. (2018). Update on the randomised phase Ib/II study of the selective small molecule AXL inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma. (external link)

Doctoral dissertation

• Schuster, Cornelia; Straume, Oddbjørn (2016). Investigation of predictive markers in patients with metastatic melanoma treated with bevacizumab. (external link)

See a complete overview of publications in Cristin.